Teva Pharm Stock Price, News & Analysis

Teva (NYSE: TEVA) said Richard Francis, Teva's President and CEO, will present at two investor conferences in November 2025: UBS Global Healthcare Conference on Monday, November 10, 2025 at 8:45 AM ET and Jefferies London Healthcare Conference on Tuesday, November 18, 2025 at 11:00 AM GMT (6:00 AM ET).

Live webcasts will be available on Teva’s Investor Relations website and archived within 24 hours after each presentation.

Teva (NYSE: TEVA) entered a license and supply agreement with Prestige Biopharma to commercialize Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.

Tuznue® is approved for breast cancer and metastatic gastric cancer and received European Commission marketing authorization in September 2024. Under the deal, Prestige will produce and supply Tuznue® from its EU‑GMP, single‑use facilities while Teva will market and distribute using its European biosimilars commercial network.

Teva (NYSE: TEVA) announced FDA approval (Oct 10, 2025) of UZEDY® (risperidone) extended‑release injectable suspension for subcutaneous once‑monthly use as monotherapy or adjunctive therapy with lithium or valproate for maintenance treatment of bipolar I disorder (adults).

Approval uses Model‑Informed Drug Development (MIDD) plus prior risperidone data; three monthly dose options are approved: 50 mg, 75 mg, 100 mg. UZEDY reaches therapeutic blood concentrations within 6–24 hours and previously received U.S. approval for adult schizophrenia in 2023. The formulation uses Medincell’s SteadyTeq copolymer for controlled release.

Teva Pharmaceutical Industries (NYSE:TEVA) has released its Q3 2025 Aide Memoire document, which is now accessible on the company's investor relations website. This document serves as a financial modeling aid for investors and analysts, incorporating historical performance data, management's business outlook commentary, and selected third-party information.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its third quarter 2025 financial results announcement for November 5, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.

Participants must register in advance to receive local or toll-free phone numbers and personal pins. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.

Teva Pharmaceuticals (NYSE: TEVA) presented positive real-world survey data for AUSTEDO XR® (deutetrabenazine) at the 2025 Psych Congress Annual Meeting. The survey of 209 tardive dyskinesia (TD) patients showed remarkable treatment satisfaction, with over 94% reporting movement improvement and more than 89% expressing high satisfaction with the treatment.

Key findings revealed that 77% of patients reported improved social comfort and emotional well-being, while 96% found the medication easy to take. The study included both patients with prior valbenazine use and those without prior treatment, with 96% of participants expressing interest in continuing AUSTEDO XR treatment.

Teva Pharmaceuticals (NYSE:TEVA) announced promising long-term safety data from its Phase 3 SOLARIS trial for olanzapine LAI (TEV-'749), a potential first-in-class long-acting injectable olanzapine treatment for schizophrenia. The trial demonstrated no post-injection delirium/sedation syndrome (PDSS) events through Week 56, with 3,470 total injections administered.

Key findings include a consistent safety profile with other olanzapine formulations, with 74% of participants reporting treatment-emergent adverse events. Common side effects included weight increase (36%) and injection site reactions. The study showed stable symptom improvement and maintained clinical effectiveness, with participants experiencing a mean weight increase of 5.6kg over 48 weeks.

Additionally, new data on UZEDY®, Teva's approved extended-release injectable risperidone, showed a 2.89-day shorter hospital stay compared to Invega Sustenna®, potentially saving $3,200 per hospitalization. Teva plans to submit an NDA for olanzapine LAI in H2 2025.

Teva Pharmaceutical (NYSE:TEVA) has announced plans to present data from its completed Phase 3 SOLARIS trial for Olanzapine LAI (TEV-'749) at the 2025 Psych Congress Annual Meeting in San Diego from September 17-21, 2025.

The company will host an analyst and investor conference call on September 22, 2025, at 11:00 a.m. ET to discuss the trial results. Participants must register in advance to obtain call-in details, and a live webcast will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the discussion.

Teva Pharmaceuticals (NYSE: TEVA) announced that the FDA has granted Fast Track designation for emrusolmin (TEV-56286), their investigational treatment for Multiple System Atrophy (MSA). The drug, currently in Phase 2 development, targets the alpha synuclein protein involved in MSA pathogenesis.

Emrusolmin, developed in collaboration with MODAG GmbH, previously received Orphan Drug designation in 2022. The Fast Track status aims to expedite the development and review process for this potential treatment of MSA, a rare and progressive neurodegenerative disorder with no current cure or disease-modifying treatments.